In fact, these DC (named as IFN-DC) exhibit a unique attitude to take-up tumor apoptotic bodies and induce a potent tumor specific T cell immunity in preclinical models [70] as well as in cancer patients, as suggested by results in pilot clinical trials where IFN-DC have been inoculated intratumorally in patients with metastatic melanoma [71] and indolent lymphomas [72]. Here, IFNA1 is linked to metastatic melanoma.